| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.022 | 0.9 |
| mRNA | selumetinib:BRD-A02303741 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | 0.014 | 0.9 |